Bonviva

Bonviva

ibandronic acid

Manufacturer:

Takeda

Distributor:

DKSH
Concise Prescribing Info
Contents
Ibandronic acid
Indications/Uses
Postmenopausal osteoporosis, to reduce the risk of fractures.
Dosage/Direction for Use
Administration
Should be taken on an empty stomach: Take at least 1 hr before the 1st food/drink/medication of the day w/ a full glass of plain water & remain in sitting/upright position for at least 1 hr. Swallow whole, do not chew/crush/suck.
Contraindications
Hypersensitivity. Esophageal abnormalities eg, stricture or achalasia, uncorrected hypocalcemia, inability to stand or sit upright for at least 60 min.
Special Precautions
Active upper GI problems (eg, Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis or ulcers). Discontinue use in case dysphagia, odynophagia, retrosternal pain or new or worsening heartburn occur. Osteonecrosis of the jaw; dental surgery. Correct hypocalcemia & other bone & mineral metabolism disturbances prior to treatment. Concomitant use w/ NSAIDs. Severe renal impairment. Not to be used during pregnancy & lactation. Childn <18 yr.
Adverse Reactions
GERD, diarrhoea, abdominal pain, dyspepsia, nausea, flatulence; headache; influenza-like illness, fatigue; arthralgia, myalgia; rash.
Drug Interactions
Interfered absorption w/ Ca-, Al-, Mg-, Fe-containing products including milk & food. Increased bioavailability w/ IV ranitidine. Concomitant use of aspirin or NSAIDs.
ATC Classification
M05BA06 - ibandronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Presentation/Packing
Form
Bonviva FC tab 150 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in